
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Future of FDA Enforcement: How Artificial Intelligence Is Changing Drug Advertising Compliance
2
Nerandomilast Receives FDA Approval for Idiopathic Pulmonary Fibrosis
3
GLP-1 Agonists May Interfere with PET-CT Scan Interpretation
4
Novel Drug Combo Improves Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer
5